You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company's adaptive low-resource testing technology requires no instrumentation and limited equipment, making it adaptable to settings without clinical lab infrastructure.
More than a dozen studies have been published to date directly comparing molecular diagnostic COVID-19 tests, with some detecting differences, mostly in sensitivity.
The acquisition will round out BD's molecular portfolio and be complementary to the firm's Veritor immunoassay system, according to executives.
The test is expected to run on Tangen's GeneSpark nucleic acid amplification platform and achieve a CLIA waiver for use in doctors' offices.
The Atila iAMP test was granted Emergency Use Authorization earlier this week and is being evaluated in multiple US labs.
The UK-based firm anticipates that it will have a high sensitivity test available in a few months that can detect active infections.
Bringing testing closer to patients could be helpful, provided enough tests and instruments can be manufactured and distributed.
The ID Now COVID-19 test is the second assay from the company to receive EUA from the FDA, following the same designation issued to the Abbott RealTime SARS CoV-2.
The molecular assay is expected to require a pharyngeal throat swab to deliver diagnostic results on a paper strip in under 30 minutes.
The system showed good performance for cervical samples as well as orophyrengeal samples, and required no extraction step.